NCT07081334View on ClinicalTrials.gov

A Phase 1 Study of PV-001 9-valent Human Papillomavirus(HPV) Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 17, 2022

Primary Completion Date

April 29, 2024

Study Completion Date

January 30, 2025

Conditions
HPV Infections
Interventions
BIOLOGICAL

PV-001

9-valent vaccine containing antigens for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58

BIOLOGICAL

PEV-001

PEV-001 is a formulation of the PV-001 vaccine that excludes the HPV antigens and contains only aluminum phosphate.

Trial Locations (1)

Unknown

Gangnam Severance Hospital, Seoul

All Listed Sponsors
lead

POSVAX

OTHER